What is the 13F Pro Quality Score for CELZ?

13F Pro ranks CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CELZ's current score at https://13fpro.ai/research/CELZ (free sign-up required for the full ranking).

Where does 13F Pro source CELZ data?

All CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. fundamentals and ownership data come directly from SEC EDGAR. CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. files with the SEC under CIK 1187953. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CELZ in?

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CELZ research updated on 13F Pro?

CELZ's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.(CELZ)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1187953 CELZ stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.2M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

CELZ Stock Analysis & AI Quality Score

AI stock analysis and institutional research for CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ), a Healthcare sector company. CELZ is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.2m in revenue. Based on the latest XBRL financial filings (Q1 2026), CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. reports net income of $-1.4M, free cash flow of $-1.3M. Top institutional holders of CELZ by reported 13-F value include GEODE CAPITAL MANAGEMENT,, VANGUARD CAPITAL MANAGEMENT, XTX Topco Ltd, based on the most recent SEC filings. CELZ trades on the Nasdaq exchange and files with the SEC under CIK 1187953. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CELZ daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. directly from SEC EDGAR.

Revenue

Q1 2026

$0.00

Net Income

Q1 2026

$-1.4M

Free Cash Flow

Q1 2026

$-1.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-45.5% YoY

$6.0KFY 2025

FY22 $88.6KFY23 $9.0KFY24 $11.0KFY25 $6.0K

Net Income

-9.1% YoY

$-6.0MFY 2025

FY22 $-10.1MFY23 $-5.3MFY24 $-5.5MFY25 $-6.0M

Operating Income

-6.9% YoY

$-6.1MFY 2025

FY22 $-10.2MFY23 $-5.6MFY24 $-5.7MFY25 $-6.1M

EPS (Diluted)

+32.1% YoY

$-2.52FY 2025

FY22 $-0.93FY23 $-3.76FY24 $-3.71FY25 $-2.52

Total Assets

+17.1% YoY

$7.8MFY 2025

FY22 $19.2MFY23 $10.7MFY24 $6.7MFY25 $7.8M

Op. Cash Flow

-10.5% YoY

$-5.9MFY 2025

FY22 $-7.8MFY23 $-8.0MFY24 $-5.3MFY25 $-5.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2018
Revenue	$6.0K -45.5%	$11.0K +22.2%	$9.0K -89.8%	$88.6K +1.0%	$87.8K -29.5%	$124.4K
Net Income	$-6.0M -9.1%	$-5.5M -3.9%	$-5.3M +47.9%	$-10.1M -152.8%	$19.2M +240.7%	$-13.7M
Operating Income	$-6.1M -6.9%	$-5.7M -2.2%	$-5.6M +45.1%	$-10.2M -227.7%	$-3.1M -180.5%	$-1.1M
EPS (Diluted)	$-2.52 +32.1%	$-3.71 +1.3%	$-3.76 -304.3%	$-0.93 -116.6%	$5.61	—
Total Assets	$7.8M +17.1%	$6.7M -37.8%	$10.7M -44.2%	$19.2M +70.3%	$11.3M +2261.5%	$477.2K
Operating Cash Flow	$-5.9M -10.5%	$-5.3M +34.0%	$-8.0M -3.0%	$-7.8M -251.9%	$-2.2M -110.6%	$-1.1M

AI Insight: CELZ Financial Trends

CELZ remains a pre-revenue clinical-stage company with persistent quarterly cash burn and no near-term commercialization signal.

• Revenue has been $0M across all eight quarters from Q2 2024 through Q1 2026, confirming zero commercial activity.

• Net losses have ranged from -$1M to -$2M per quarter, with no improvement trend over the eight-quarter span.

• Equity has oscillated between $6M and $8M, suggesting periodic equity raises are offsetting ongoing losses.

⚠ Equity fell to $6M in Q1 2026, matching prior lows; continued burn without new capital raises further dilution or insolvency risk.

⚠ Operating cash outflow has held at -$1M to -$2M per quarter; any acceleration would compress the apparent runway quickly.

AI Insight: CELZ Ratio Trends

CELZ shows persistently deep negative returns with ROE and ROIC worsening in the TTM period, signaling no clear path to profitability.

• ROE deteriorated from -63.4% in Q3 2024 to -92.0% in Q1 2026, with the TTM reading at -94.3%.

• ROA swung from -60.4% in Q3 2024 to -87.3% in Q1 2026, reflecting sustained asset-level losses.

• ROIC reached -95.5% in Q1 2026 versus -67.7% in Q3 2024, indicating deepening capital destruction.

⚠ OpMargin, NPM, and D/E are absent across all periods — too sparse to assess cost structure or leverage.

⚠ ROE hit -117.0% in Q4 2024, a sharp spike; recurrence would signal accelerating cash burn.

Get alerted when CELZ's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CELZ

GEODE CAPITAL MANAGEMENT, LLC
$78.9K38,290 sh
VANGUARD CAPITAL MANAGEMENT LLC
$41.9K20,350 sh
XTX Topco Ltd
$29.4K14,260 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$21.6K10,469 sh
VANGUARD FIDUCIARY TRUST CO
$11.4K5,518 sh
WELLS FARGO & COMPANY/MN
$10.3K5,000 sh
Tower Research Capital LLC (TRC)
$4.3K2,092 sh
MORGAN STANLEY
$1.1K534 sh
FMR LLC
$515.00250 sh
SBI Securities Co., Ltd.
$2.001 sh

Fund	Value	Shares
GEODE CAPITAL MANAGEMENT, LLC	$78.9K	38,290
VANGUARD CAPITAL MANAGEMENT LLC	$41.9K	20,350
XTX Topco Ltd	$29.4K	14,260
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$21.6K	10,469
VANGUARD FIDUCIARY TRUST CO	$11.4K	5,518
WELLS FARGO & COMPANY/MN	$10.3K	5,000
Tower Research Capital LLC (TRC)	$4.3K	2,092
MORGAN STANLEY	$1.1K	534
FMR LLC	$515.00	250
SBI Securities Co., Ltd.	$2.00	1

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CELZ on your watchlist

Track score changes the day CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CELZ a good stock to buy?

13F Pro's AI-powered analysis of CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CELZ are available on the CELZ stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CELZ?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CELZ. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.'s investment landscape.